Biotech | November 02, 2021
AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
The division is expected to grow to over a 100-member strong team by 2022
Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
It paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Subscribe To Our Newsletter & Stay Updated
